PRESERVATION I Study is Key Upcoming Milestone for BioLineRx (BLRX); Roth Affirms at 'Buy'
Tweet Send to a Friend
Roth Capital affirms BioLineRx, Ltd. (Nasdaq: BLRX) at Buy with a price target of $10.50 following FY14 results reported earlier.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
